Advertisement
Advertisement
ABVX
Abivax SA - ADR
126.08
USDSponsored
+0.39
+0.31%
Apr 10, 15:59 UTC -4
Closed
After-Market
126.74
+0.66
+0.53%
ABVX Earnings Reports
Positive Surprise Ratio
ABVX beat 2 of 6 last estimates.
33%
Next Report
Date of Next Report
May 25, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Abivax SA - ADR earnings per share and revenue
On Mar 23, 2026, ABVX reported earnings of -3.24 USD per share (EPS) for Q4 25, missing the estimate of -1.52 USD, resulting in a -112.47% surprise. Revenue reached 2.48 million, compared to an expected 2.04 million, with a 21.72% difference. The market reacted with a -4.55% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Pharvaris N.V. Ordinary Shares
Report Date
Apr 02, 2026 For Q4 25
Estimate
-$0.63
Actual
-$0.72
Surprise
-13.69%
Innate Pharma S.A. ADS
Report Date
Apr 01, 2026 For Q1 26
Estimate
-$0.12
Actual
-$0.55
Surprise
-353.80%
MiNK Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.83
Actual
-$0.55
Surprise
+33.64%
Kairos Pharma, Ltd.
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.07
Surprise
-28.68%
Imunon, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.19
Actual
-$1.99
Surprise
-66.18%
Soligenix, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$0.57
Actual
-$0.28
Surprise
+50.98%
Cadrenal Therapeutics, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$1.18
Actual
-$1.43
Surprise
-20.34%
BioAtla, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$12.24
Actual
-$8.00
Surprise
+34.64%
Sunshine Biopharma Inc.
Report Date
Apr 03, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.54
Surprise
-96.08%
CNS Pharmaceuticals, Inc. Common Stock
Report Date
Mar 31, 2026 For Q4 25
Estimate
-$5.19
Actual
-$10.15
Surprise
-95.50%
FAQ
What were Abivax SA - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Abivax SA - ADR reported EPS of -$3.24, missing estimates by -112.47%, and revenue of $2.48M, 21.72% above expectations.
How did the market react to Abivax SA - ADR's Q4 2025 earnings?
The stock price moved down -4.55%, changed from $115.42 before the earnings release to $110.17 the day after.
When is Abivax SA - ADR expected to report next?
The next earning report is scheduled for May 25, 2026.
What are the forecasts for Abivax SA - ADR's next earnings report?
Based on --
analysts, Abivax SA - ADR is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement